Summary
MAH0 Chart
Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Mereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meeting early efficacy stopping criteria of ORBIT, not due to safety or trial failure. The ongoing phase 2/3 ORBIT study is targeting OI patients ages 5 to 25, while the phase 3 COSMIC trial is going after patients ages 2 to < 7 years.
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?
MEREO BIOPHARMA (MREO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a partner for Alvelestat's phase 3 trial, potentially boosting stock value.
Mereo BioPharma Group plc - ADR (MAH0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mereo BioPharma Group plc - ADR ever had a stock split?
Mereo BioPharma Group plc - ADR Profile
| Biotechnology Industry | Healthcare Sector | Denise Vera Scots-Knight CEO | XMUN Exchange | US5894921072 ISIN |
| GB Country | 36 Employees | - Last Dividend | - Last Split | 24 Apr 2019 IPO Date |
Overview
Mereo BioPharma Group plc operates as a biopharmaceutical company engaged in the development and commercialization of innovative therapeutics aimed at addressing oncology and rare diseases. Operating both within the United Kingdom and internationally, the company focuses on advancing its lead product candidates through various stages of clinical trials. Founded in 2015 and based in London, United Kingdom, Mereo BioPharma has established collaborations with significant institutions such as The University of Texas MD Anderson Cancer Center and holds a licensing agreement with Ultragenyx Pharmaceutical Inc. for the development and commercialization of one of its key rare disease product candidates.
Products and Services
List and explanation of the company's lead product candidates:
- Etigilimab (OMP-313M32): A promising immunotherapy candidate targeting T-cell receptors, etigilimab is an antibody in Phase 1b clinical trial aimed at treating tumors through enhancing immune system responses against cancer cells.
- Navicixizumab (OMP-305B83): This completed Phase 1b clinical trials as a therapeutic approach for treating late-line ovarian cancer, showcasing the company’s dedication to addressing hard-to-treat cancers.
- Acumapimod (BCT-197): Targeting a key inflammatory pathway with a p38 MAP kinase inhibitor, Acumapimod is in Phase II clinical trials intended for patients suffering from acute exacerbations of chronic obstructive pulmonary disease (COPD).
- Leflutrozole (BGS-649): As an oral aromatase inhibitor, Leflutrozole is undergoing Phase 2 trials, aiming to address hypogonadotropic hypogonadism, which is a condition characterized by low testosterone levels due to insufficient gonadotropin production.
In addition, Mereo BioPharma is developing rare disease product candidates such as:
- Setrusumab (BPS-804): An innovative antibody in development for osteogenesis imperfecta, also known as brittle bone disease, which underscores the company’s commitment to tackling rare genetic disorders.
- Alvelestat (MPH-966): This oral small molecule antagonist aims at treating Alpha-1 anti-trypsin deficiency, currently in Phase II clinical trial, showcasing Mereo BioPharma's expertise in targeting rare pulmonary conditions.
Contact Information
